The St Thomas’ Atherosclerosis Regression Study and an appraisal of its potential limitations

  • G. F. Watts
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 180)


The principal findings and potential limitations of the St Thomas’ Atherosclerosis Regression Study (STARS) are presented. STARS was a randomized endpoint blinded study of the effects of lipid-lowering therapy on angiographic coronary artery disease (CAD) in male patients with hypercholesterolemia. Both a fat-modified diet and diet-plus cholestyramine favourably influenced the course of CAD over 3 years. As discussed in this paper, the study did, however, have some limitations in respect of its sample size, use of angiography and generalizability of the findings.


Coronary Atherosclerosis Quantitative Coronary Angiography Coronary Segment Percentage Diameter Stenosis Angiographic Coronary Artery Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Arntzenius AC, Kromhout D, Barth JD, et al. Diet, lipoproteins and the progression of coronary atherosclerosis. N Engl J Med. 1985;312:805–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990;336:129–33.PubMedCrossRefGoogle Scholar
  3. 3.
    Schuler G, Hambrecht R, Schlierf G, et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation. 1992;86:1–11.PubMedGoogle Scholar
  4. 4.
    Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression Study (STARS). Lancet. 1992;339:536–69.Google Scholar
  5. 5.
    Choudhury S, Jackson P, Katan MB, et al. A multifactorial diet in the management of hyperlipidaemia. Atherosclerosis. 1984;50:93–103.PubMedCrossRefGoogle Scholar
  6. 6.
    Gotto AM Jr, Bierman EL, Connor WE, et al. Recommendations for the treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Atherosclerosis. Circulation. 1984;69:1065A–90A.PubMedCrossRefGoogle Scholar
  7. 7.
    Watts GF. Lipid-lowering therapy and regression of atherosclerosis. Endocrinol Metab. 1994;1:71–87.Google Scholar
  8. 8.
    Watts GF, Mandalia S, Brunt JNH, et al. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St Thomas’ Atherosclerosis Regression Study (STARS). Metabolism. 1993;42:1461–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Watts GF, Jackson P, Brunt JNH, et al. Nutrient intake and progression of coronary artery disease. Am J Cardiol. 1994;73:328–32.PubMedCrossRefGoogle Scholar
  10. 10.
    Blankenhorn DH, Johnson RL, Mack WJ, et al. The influence of diet on the appearance of new lesions in human coronary arteries. JAMA. 1990;263:1646–52.PubMedCrossRefGoogle Scholar
  11. 11.
    Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings by age for 316,099 men. Arch Intern Med. 1992;152:56–64.PubMedCrossRefGoogle Scholar
  12. 12.
    Blankenhorn DM, Kramsch DM. Reversal of atherosis and sclerosis. Circulation. 1989;79:1–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation. 1990;82:1916–24.PubMedCrossRefGoogle Scholar
  14. 14.
    Pocock SJ. Clinical trials: a practical approach. Chichester: John Wiley & Sons; 1983.Google Scholar
  15. 15.
    Duffield RGM, Lewis B, Miller NE, et al. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis: a randomized controlled trial. Lancet. 1983;2:639–42.PubMedCrossRefGoogle Scholar
  16. 16.
    Azen S, Blankenhorn DH, Nessim S. Planning and evaluation of studies on atherosclerosis in controlled clinical trials. In: Malinow MR, Blaton VH, editors. Regression of atherosclerotic lesions: experimental studies and observations in humans. New York: Plenum; 1984:263–75.Google Scholar
  17. 17.
    Olsson A. Regression of femoral atherosclerosis. Circulation. 1991;83:698–700.PubMedGoogle Scholar
  18. 18.
    Gibson CM, Sandor T, Stone PH, et al. Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for regression trials. Am J Cardiol. 1992;69:1286–90.PubMedCrossRefGoogle Scholar
  19. 19.
    Oliver MR Serum cholesterol — the knave of hearts and the joker. Lancet. 1981;2:1090–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Blankenhorn DM, Hodis HN. Arterial imaging and atherosclerosis reversal. Arterioscler Thromb. 1994;14:177–92.PubMedCrossRefGoogle Scholar
  21. 21.
    Brown BG, Bolson EL, Dodge HT. Arteriographic assessment of coronary atherosclerosis: review of current methods, their limitations, and clinical applications. Arteriosclerosis. 1982;2:2–15.PubMedCrossRefGoogle Scholar
  22. 22.
    Waters D, Craven TE, Esperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation. 1993;87:1067–75.PubMedGoogle Scholar
  23. 23.
    Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerosis progression. Circulation. 1993;87(Suppl):II56–65.PubMedGoogle Scholar
  24. 24.
    Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233–40.PubMedCrossRefGoogle Scholar
  25. 25.
    Katan MB, Birgelen AV, Deslypere JP, et al. Biological markers of dietary intake, with emphasis on fatty acids. Ann Nutr Metab. 1991;35:249–52.PubMedCrossRefGoogle Scholar
  26. 26.
    Chait A. Methods for assessing lipid and lipoprotein oxidation. Curr Opin Lipidol. 1992;3:389–94.CrossRefGoogle Scholar
  27. 27.
    Witztum JL. Role of oxidized low density lipoprotein in atherogenesis. Br Heart J. 1993;69(Suppl):12–8.CrossRefGoogle Scholar
  28. 28.
    Hamsten A. Coagulation factors and hyperlipidaemia. Curr Opin Lipidol. 1991;2:266–71.CrossRefGoogle Scholar
  29. 29.
    Watts GF, Mandalia S, Brunt JNH, et al. Metabolic determinants of the course of coronary artery disease in men. Clin Chem. 1995;40:2240–6.Google Scholar
  30. 30.
    Lewis B, Hammett F, Katan MB, et al. Towards an improved lipid-lowering diet: additive effects of changes in nutrient intake. Lancet. 1982;2:1310–13.Google Scholar
  31. 31.
    Mulcahy D, Kehely A, Fox K, et al. Risk reduction in patients with coronary artery disease: lipids and lost opportunities. Br J Cardiol. 1994;1:161–5.Google Scholar
  32. 32.
    Cohen MV, Byrne MJ, Levine B, et al. Low rate of treatment of hypercholesterolaemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation. 1992;83:1294–304.Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • G. F. Watts

There are no affiliations available

Personalised recommendations